Commodore Capital LP Immunovant, Inc. Transaction History

Commodore Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$30.27 - $43.79 $7.54 Million - $10.9 Million	-249,010 Reduced 24.9%	750,990 $24.3 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $1.86 Million - $4 Million	100,000 Added 11.11%	1,000,000 $38.4 Million
Q2 2023 Aug 14, 2023	SELL	$14.2 - $23.75 $7.68 Million - $12.8 Million	-540,999 Reduced 37.54%	900,000 $17.1 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $4.44 Million - $5.73 Million	290,494 Added 25.25%	1,440,999 $22.3 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $7.58 Million - $20.4 Million	1,150,505 New	1,150,505 $20.4 Million
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $1.1 Million - $4.16 Million	-83,782 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $3.05 Million - $4.42 Million	83,782 New	83,782 $3.87 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.